echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Announcement of the State Drug Administration on Revising the Instructions for Oxaliplatin Preparations (No. 102 of 2021)

    Announcement of the State Drug Administration on Revising the Instructions for Oxaliplatin Preparations (No. 102 of 2021)

    • Last Update: 2021-11-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    According to the evaluation results of adverse drug reactions, in order to further protect the safety of public medication, the National Medical Products Administration has decided to treat oxaliplatin preparations (including oxaliplatin for injection, oxaliplatin injection, oxaliplatin mannitol injection) ) The contents of the manual are revised uniformly
    The relevant matters are hereby announced as follows: 1.
    The marketing authorization holders of the above-mentioned drugs shall be in accordance with the "Administrative Measures for Drug Registration" and other relevant regulations, in accordance with the requirements for the revision of the oxaliplatin preparation instructions (see attachment), before November 22, 2021 Report to the provincial drug supervision and administration department for the record
    If the revised content involves the label of a drug, it shall be revised together; the instructions and other content of the label shall be consistent with the original approved content
    Drugs produced on the date of filing shall not continue to use the original drug instructions
    The holder of the drug marketing authorization shall replace the instructions and labels of the drugs that have been shipped out of the factory within 9 months after filing
    The drug marketing license holder shall conduct in-depth research on the mechanism of new adverse reactions, take effective measures to conduct publicity and training on drug use and safety issues, and guide physicians and pharmacists to use drugs rationally
    Clinicians and pharmacists should carefully read the revised contents of the above-mentioned drug inserts, and when choosing medications, they should conduct a sufficient benefit/risk analysis based on the newly revised inserts
    The patient should read the drug insert carefully before taking the medicine.
    If using prescription drugs, they should strictly follow the doctor's advice
    The provincial drug supervision and administration department shall supervise and urge the drug marketing license holders of the above-mentioned drugs in the administrative area to do the corresponding manual revision and label and manual replacement work as required, and strictly investigate and deal with violations of laws and regulations in accordance with the law
    Hereby announce
    Attachment: Requirement for the revision of the oxaliplatin preparation instructions.
    National Medical Products Administration August 23, 2021 National Medical Products Administration Announcement No.
    102 of 2021 Annex.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.